Prospective Safety and Feasibility trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)

被引：0
|
作者：
All, S. [1 ]
de Leon, A. Diaz [2 ]
Mohamad, O. [3 ]
Choy, H. [4 ]
Hammers, H. [5 ]
Sanjeevaiah, A. [6 ]
Arafat, W. [6 ]
Courtney, K. [5 ]
Timmerman, R. D. [4 ]
Brugarolas, J. [7 ]
Hannan, R. [4 ]
机构：
[1] UT Southwestern, Dept Radiat Oncol, Dallas, TX USA
[2] UT Southwestern, Dept Radiol, Dallas, TX USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[6] UT Southwestern, Dept Hematol Oncol, Dallas, TX USA
[7] Univ Texas Southwestern Med Ctr Dallas, Dept Hematol Oncol, Dallas, TX 75390 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 108卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4086
引用
收藏
页码：E896 / E897
页数：2
相关论文
共 50 条
  • [1] Stereotactic Radiation Therapy (SRT) for Metastatic Renal Cell Carcinoma (mRCC)
    Meyer, E.
    Pasquier, D.
    Bernadou, G.
    Calais, G.
    Carrie, C.
    Stefan, D.
    Theodore, C.
    Albiges, L.
    Bossi, A.
    Maroun, P.
    De Crevoisier, R.
    Hennequin, C.
    Lagrange, J. L.
    Lesaunier, F.
    Grellard, J. M.
    Clarisse, B.
    Habrand, J. L.
    Dugue, A. E.
    Joly, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E247 - E248
  • [2] Phase 2 Trial of High-Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)-Interim Analysis of i-SAbR IL-2 Trial
    Ishihara, D.
    Louder, K.
    Akter, M.
    Ahn, C.
    Margulis, V.
    Arriaga, Y.
    Courtney, K.
    Timmerman, R. D.
    Brugarolas, J.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S96 - S97
  • [3] Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab
    Mohammadi, H.
    Tolpin, A. B.
    Peacock, J.
    Oliver, D. E.
    Sim, A. J.
    Palm, R.
    Ahmed, K. A.
    Liu, J. K.
    Tran, N.
    Etame, A. B.
    Robinson, T. J.
    Yu, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E82 - E82
  • [4] Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
    Schoenhals, Jonathan E.
    Mohamad, Osama
    Christie, Alana
    Zhang, Yuanyuan
    Li, Daniel
    Singla, Nirmish
    Bowman, Isaac
    Arafat, Waddah
    Hammers, Hans
    Courtney, Kevin
    Cole, Suzanne
    Bagrodia, Aditya
    Margulis, Vitaly
    Desai, Neil
    Garant, Aurelie
    Choy, Hak
    Timmerman, Robert
    Brugarolas, James
    Hannan, Raquibul
    ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (05)
  • [5] Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases
    Wang, Chiachien Jake
    Christie, Alana
    Lin, Mu-Han
    Jung, Matthew
    Weix, Derek
    Huelsmann, Lorel
    Kuhn, Kristin
    Meyer, Jeffrey
    Desai, Neil
    Kim, D. W. Nathan
    Pedrosa, Ivan
    Margulis, Vitaly
    Cadeddu, Jeffrey
    Sagalowsky, Arthur
    Gahan, Jeffrey
    Laine, Aaron
    Xie, Xian-Jin
    Choy, Hak
    Brugarolas, James
    Timmerman, Robert
    Hannan, Raquibul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 91 - 100
  • [6] Predictive Factors for Oliogometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Ablative Radiation (SAbR)
    Yen, A.
    Tang, S.
    Christie, A.
    Kwon, J.
    Miljanic, M.
    Song, T.
    Garant, A.
    Yang, D. X.
    Brugarolas, J.
    Timmerman, R. D.
    Wang, J.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E599 - E599
  • [7] Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer
    Zhang, Yuanyuan
    Schoenhals, Jonathan
    Christie, Alana
    Mohamad, Osama
    Wang, Chiachien
    Bowman, Isaac
    Singla, Nirmish
    Hammers, Hans
    Courtney, Kevin
    Bagrodia, Aditya
    Margulis, Vitaly
    Desai, Neil
    Garant, Aurelie
    Choy, Hak
    Timmerman, Robert
    Brugarolas, James
    Hannan, Raquibul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (02): : 367 - 375
  • [8] Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies
    Zaorsky, Nicholas G.
    Lehrer, Eric J.
    Kothari, Gargi
    Louie, Alexander, V
    Siva, Shankar
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (05): : 515 - 523
  • [9] TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC)
    Barthelemy, P.
    Escudier, B.
    Ravaud, A.
    Negrier, S.
    Needle, M. N.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 311 - 311
  • [10] Association of microbiome to nivolumab response in metastatic renal cell carcinoma (mRCC)
    Maia, Manuel
    Poroyko, Valeriy
    Won, Hae
    Bergerot, Paulo
    Almeida, Lorena
    Dizman, Nazli
    Hsu, JoAnn
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345